DPP-4 inhibitors for the treatment of type 2 diabetes: a methodology overview of systematic reviews

被引：0
|
作者：
Juan Ling
Long Ge
Ding-hua Zhang
Yong-feng Wang
Zhuo-lin Xie
Jin-hui Tian
Xiao-hui Xiao
Ke-hu Yang
机构：
[1] Lanzhou University,School of Basic Medical Sciences, Evidence
[2] Key Laboratory of Evidence Based Medicine and Knowledge Translation of Gansu Province,Based Medicine Center
[3] Lanzhou University,Chinese GRADE Center
[4] WHO Collaborating Center for Guideline Implementation and Knowledge Translation,School of Basic Medical Sciences
[5] The First Clinical Medical College of Lanzhou University,Department of Endocrinology
[6] Gansu University of Traditional Chinese Medicine,undefined
[7] Gansu University of Traditional Chinese Medicine,undefined
[8] Gansu Province Hospital of Traditional Chinese Medicine,undefined
[9] Gansu Provincial People’s Hospital,undefined
来源：
Acta Diabetologica | 2019年 / 56卷
关键词：
Dipeptidyl peptidase 4 inhibitors; Systematic reviews; Type 2 diabetes mellitus; AMSTAR; GRADE;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：7 / 27
页数：20
相关论文
共 50 条
  • [1] DPP-4 inhibitors for the treatment of type 2 diabetes: a methodology overview of systematic reviews
    Ling, Juan
    Ge, Long
    Zhang, Ding-hua
    Wang, Yong-feng
    Xie, Zhuo-lin
    Tian, Jin-hui
    Xiao, Xiao-hui
    Yang, Ke-hu
    ACTA DIABETOLOGICA, 2019, 56 (01) : 7 - 27
  • [2] A Clinical Overview of DPP-4 Inhibitors for Type 2 Diabetes
    Jeon, Michelle
    Took, Roxane L.
    Peters, Golden L.
    US PHARMACIST, 2018, 43 (10) : 49 - 56
  • [3] DPP-4 inhibitors in the treatment of type 2 diabetes
    Duez, Helene
    Cariou, Bertrand
    Staels, Bart
    BIOCHEMICAL PHARMACOLOGY, 2012, 83 (07) : 823 - 832
  • [4] Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes
    Sutton, Jon M.
    Clark, David E.
    Dunsdon, Stephen J.
    Fenton, Garry
    Fillmore, Amanda
    Harris, Neil V.
    Higgs, Chris
    Hurley, Chris A.
    Krintel, Sussie L.
    MacKenzie, Robert E.
    Duttaroy, Alokesh
    Gangl, Eric
    Maniara, Wiesia
    Sedrani, Richard
    Namoto, Kenji
    Ostermann, Nils
    Gerhartz, Bernd
    Sirockin, Finton
    Trappe, Joerg
    Hassiepen, Ulrich
    Baeschlin, Daniel K.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (03) : 1464 - 1468
  • [5] Need for streamlined use of DPP-4 inhibitors in the treatment of type 2 diabetes
    Cristiana Vitale
    Giuseppe M. C. Rosano
    Krishna Prasad
    Cardiovascular Diabetology, 15
  • [6] Type 2 Diabetes Comorbidities and Treatment Challenges: Rationale for DPP-4 Inhibitors
    Hollander, Priscilla A.
    Kushner, Pamela
    POSTGRADUATE MEDICINE, 2010, 122 (03) : 71 - 80
  • [7] Will DPP-4 inhibitors replace sulfonylureas in the treatment of type 2 diabetes? Pro
    Nauck, M. A.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2011, 136 (11) : 546 - 546
  • [8] Need for streamlined use of DPP-4 inhibitors in the treatment of type 2 diabetes
    Vitale, Cristiana
    Rosano, Giuseppe M. C.
    Prasad, Krishna
    CARDIOVASCULAR DIABETOLOGY, 2016, 15
  • [9] Peptide degradation and the role of DPP-4 inhibitors in the treatment of type 2 diabetes
    Deacon, Carolyn F.
    PEPTIDES, 2018, 100 : 150 - 157
  • [10] Will DPP-4 inhibitors replace sulfonylureas in the treatment of type 2 diabetes? Contra
    Mueller, U. A.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2011, 136 (11) : 547 - 547
12345